Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6291075 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6181102 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6293849 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6291262 | 0.83 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6291057 | 0.83 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6777192 | 0.82 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6291225 | 0.82 | PTGS2 (0.82) | PTGS2PTGS1 | |
| SCHEMBL6290617 | 0.82 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6291096 | 0.81 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6294224 | 0.81 | PTGS2 (0.73) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743816-B2 | CYCLOOXYGENASE INHIBITORS WITH SELECTIVITY FOR THE ISOFORM 2 (COX-2); 4-CHLORO-5-(4-ISOPROPOXYPHENYL)-1-(4-METHYLSULFONYL PHENYL)IMIDAZOLE; CHLORINATION | J. URIACH & CIA S.A. (ES) | 2004-06-01 | — | — | US | claimed |
| US-20030176481-A1 | Novel imidazole derivatives with anti-inflammatory activity | J. URIACH & CIA S.A. (ES) | 2003-09-18 | — | — | US | claimed |
| EP-1270559-A1 | NOVEL IMIDAZOLE DERIVATIVES WITH ANTI-INFLAMMATORY ACTIVITY | J. URIACH & CIA. S.A. (ES) | 2003-01-02 | — | — | EP | claimed |
| US-6743816-B2 | CYCLOOXYGENASE INHIBITORS WITH SELECTIVITY FOR THE ISOFORM 2 (COX-2); 4-CHLORO-5-(4-ISOPROPOXYPHENYL)-1-(4-METHYLSULFONYL PHENYL)IMIDAZOLE; CHLORINATION | J. URIACH & CIA S.A. (ES) | 2004-06-01 | — | — | US | disclosed |
| US-20030176481-A1 | Novel imidazole derivatives with anti-inflammatory activity | J. URIACH & CIA S.A. (ES) | 2003-09-18 | — | — | US | disclosed |
| EP-1270559-A1 | NOVEL IMIDAZOLE DERIVATIVES WITH ANTI-INFLAMMATORY ACTIVITY | J. URIACH & CIA. S.A. (ES) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176481-A1 | Novel imidazole derivatives with anti-inflammatory activity | IL1B, IL1A, MIF | PTGS2 11/4885PTGS1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.